Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.

Piulats, Josep M; Vidal, August; García-Rodríguez, Francisco J; Muñoz, Clara; Nadal, Marga; Moutinho, Catia; Martínez-Iniesta, María; Mora, Josefina; Figueras, Agnés; Guinó, Elisabet; Padullés, Laura; Aytés, Àlvaro; Molleví, David G; Puertas, Sara; Martínez-Fernández, Carmen; Castillo, Wilmar; Juliachs, Merce; Moreno, Victor; Muñoz, Purificación; Stefanovic, Milica; Pujana, Miguel A; Condom, Enric; Esteller, Manel; Germà, Josep R; Capella, Gabriel; Farré, Lourdes; Morales, Albert; Viñals, Francesc; García-Del-Muro, Xavier; Cerón, Julián; Villanueva, Alberto

Piulats, Josep M; Vidal, August; García-Rodríguez, Francisco J; Muñoz, Clara; Nadal, Marga; Moutinho, Catia; Martínez-Iniesta, María; Mora, Josefina; Figueras, Agnés; Guinó, Elisabet; Padullés, Laura; Aytés, Àlvaro; Molleví, David G; Puertas, Sara; Martínez-Fernández, Carmen; Castillo, Wilmar; Juliachs, Merce; Moreno, Victor; Muñoz, Purificación; Stefanovic, Milica; Pujana, Miguel A; Condom, Enric; Esteller, Manel; Germà, Josep R; Capella, Gabriel; Farré, Lourdes; Morales, Albert; Viñals, Francesc; García-Del-Muro, Xavier; Cerón, Julián; Villanueva, Alberto.

Afiliación

Piulats JM; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Vidal A; Department of Medical Oncology, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
García-Rodríguez FJ; Department of Pathology, Hospital Universitari de Bellvitge (IDIBELL), CIBERONC, Barcelona, Spain.
Muñoz C; Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, L'Hospitalet de Llobregat, Barcelona, Spain.
Nadal M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Moutinho C; Modelling Human Diseases in C. elegans. Genes, Disease and Therapy Program (IDIBELL), Barcelona, Spain.
Martínez-Iniesta M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Mora J; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Figueras A; Cancer Epigenetics and Cell Biology Program (PEBC), Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Guinó E; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Padullés L; Department of Biochemistry, Hospital de Sant Pau, Barcelona, Spain.
Aytés À; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Molleví DG; Bioinformatic Unit, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Puertas S; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Martínez-Fernández C; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Castillo W; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Juliachs M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Moreno V; Modelling Human Diseases in C. elegans. Genes, Disease and Therapy Program (IDIBELL), Barcelona, Spain.
Muñoz P; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Stefanovic M; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Pujana MA; Bioinformatic Unit, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Condom E; Cancer Epigenetics and Cell Biology Program (PEBC), Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Esteller M; Department of Cell Death and Proliferation, Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), IDIBAPS, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Germà JR; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Capella G; Department of Pathology, Hospital Universitari de Bellvitge (IDIBELL), CIBERONC, Barcelona, Spain.
Farré L; Cancer Epigenetics and Cell Biology Program (PEBC), Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Morales A; Department of Medical Oncology, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Viñals F; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
García-Del-Muro X; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Cerón J; Laboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPQGM/FIOCRUZ), Salvador, Bahia, Brazil.
Villanueva A; Institute of Science and Technology of Tropical Diseases (INCT/DT), Salvador, Brazil.

Clin Cancer Res ; 24(15): 3755-3766, 2018 08 01.

Article en En | MEDLINE | ID: mdl-29618620

Asunto(s)

Cisplatino/efectos adversos; ADN Polimerasa III/genética; Proteínas de Unión al ADN/genética; Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico; Proteínas Nucleares/genética; Nucleoproteínas/genética; Neoplasias Testiculares/tratamiento farmacológico; Factores de Transcripción/genética; Adolescente; Adulto; Animales; Línea Celular Tumoral; Aberraciones Cromosómicas/efectos de los fármacos; Cromosomas Humanos Par 9/efectos de los fármacos; Cromosomas Humanos Par 9/genética; Cisplatino/administración & dosificación; Resistencia a Antineoplásicos/genética; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Genómica; Humanos; Masculino; Ratones; Persona de Mediana Edad; Neoplasias de Células Germinales y Embrionarias/genética; Neoplasias de Células Germinales y Embrionarias/patología; Mutación Puntual/genética; Neoplasias Testiculares/genética; Neoplasias Testiculares/patología; Ensayos Antitumor por Modelo de Xenoinjerto; Adulto Joven

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Testiculares / Factores de Transcripción / Proteínas Nucleares / Cisplatino / Neoplasias de Células Germinales y Embrionarias / Proteínas de Unión al ADN / ADN Polimerasa III / Nucleoproteínas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Animals / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google